Echinococcosis is a chronic parasitic disease and a serious zoonotic infection caused by the adult or larval stages of Echinococcus tapeworms. The transmission of Echinococcosis depends on carnivores as definitive hosts and various animals as intermediate hosts. According to current epidemiological reports, the liver is the most commonly affected organ. Clinically, Hepatic Echinococcosis is classified into hepatic alveolar Echinococcosis and hepatic cystic Echinococcosis, both of which pose a serious threat to the quality of life of residents in endemic areas. Currently, surgical treatment combined with benzimidazole medication is the main therapy; however, there are few chemotherapeutic drugs and targeted treatments available, and clinical treatment still has limitations. Therefore, there is an urgent need for new exploration in the molecular immunology, cellular directions. In recent years, with the development of high-throughput sequencing technology, integrated analyses of spatial transcriptomics and single-cell transcriptomics have become more accessible in clinical research, providing new approaches for the study of hepatic Echinococcosis. This review focuses on the application of single-cell RNA sequencing in hepaticEchinococcosis in recent years, as well as research on molecular immunopathogenesis, moleculardiagnostics, metastasis, cellular heterogeneity, growth and development, and the interactions between human hosts and echinococcosis. We pay particularly attentionto the heterogeneity of infiltrating immune cells around lesions, classification of cell subpopulations, immune suppression, and the immune microenvironment, which can help clinicians better understand the molecular immune mechanisms and biological characteristics of hepatic Echinococcosis, providing references for exploring new drug therapeutic targets.

OBJECTIVE:To develop a novel non-invasive CRISPR/Cas12a-RCA assay for the primary screening of human echinococcosis via detection of circulating Echinococcus cell-free DNA (cfDNA) in peripheral blood. METHODS:Plasma cfDNA from 20 AE patients was analyzed via high-throughput sequencing to identify conserved repetitive Echinococcus fragments.A one-pot RCA system coupled with CRISPR/Cas12a was optimized for Echinococcus-cfDNA detection. The limit of detection (LOD) was determined using serially diluted synthetic standards, while specificity was validated through mismatch probes and cross-reactivity testing. Clinical validation included 50 AE cases, 22 cystic echinococcosis (CE) cases, 43 non-Echinococcus hepatic disease (HD) cases, and 53 healthy controls (CON). RESULTS:A conserved repetitive 28S rDNA fragment (pan-Echinococcus-28S) was identified as a biomarker. The CRISPR/Cas12a-RCA assay achieved amplification within 30 minutes at 37 °C, with a linear range of 1 aM to 100 pM and an LOD of 1.41 aM. Visual detection limits were 10 aM (UV light) and 1 aM (blue light). The assay demonstrated high sensitivity (87.5%) and specificity (96.9%, AUC = 0.933) in distinguishing Echinococcus infection (AE/CE) from HD and CON. CONCLUSION:The optimized one-pot CRISPR/Cas12a-RCA system enables rapid and ultrasensitive detection of pan-Echinococcus cfDNA, providing a cost-effective and highly accurate solution for the primary screening of echinococcosis.

Echinococcosis: is a zoonotic parasitic disease caused by infection with the larvae of Echinococcus tapeworms. At present, the standardized treatment regimen for this disease consists of radical lesion resection combined with albendazole. For patients who are inoperable or experience postoperative recurrence, the treatment with anti-echinococcosis drugs is particularly crucial. To date, albendazole remains the primary drug clinically used for anti-echinococcosis treatment. However, it has inherent drawbacks such as low bioavailability, poor solubility, long treatment course, and multiple adverse reactions, which reduce the medication adherence of patients with echinococcosis and compromise the clinical therapeutic efficacy. In recent years, with the in-depth development of research in molecular biology, pharmacology, and natural medicines, significant progress has also been made in the field of anti-echinococcosis drugs. This article systematically reviews the research progress in the development of new anti-echinococcosis drugs from four aspects: structural modification and new formulations of benzimidazole drugs, targeted drug therapy, combined medication strategies, and exploration of natural medicines and active components of traditional Chinese medicines.

To investigate the effect of radical hepatectomy on the prognosis of patients with hepatic alveolar echinococcosis (HAE) complicated with microvascular invasion (MVI). HAE patients who underwent radical hepatectomy at the Echinococcosis Diagnosis and Treatment Center of Qinghai Provincial People's Hospital from January 2014 to December 2020 were collected in this study according to the inclusion and exclusion criteria. The clinical data of the patients were collected and analyzed. According to the surgical method, the patients were divided into anatomical hepatectomy group (Anatomical group) and non-anatomical hepatectomy group (Non-anatomical group). Kaplan-Meier survival analysis was used to compare the 5-year recurrence-free survival (RFS) between the two groups. A total of 375 patients were enrolled in the study (with 185 in Anatomical group and 190 in Non-anatomical group). The results of clinicopathological data analysis showed that compared with the Non-anatomical group, the patients in the Anatomical group had less intraoperative blood loss and blood transfusion, and a lower postoperative recurrence rate (all P < 0.05). The survival analysis results showed that the overall survival of the enrolled patients was 92.9%. Compared with the Non-anatomical group, the 5-year RFS of the Anatomical group was higher (98% vs. 87.7%, P < 0.05). Besides, In the Anatomical group, the 5-year RFS of patients with negative MVI was better than that of patients with positive MVI (100% vs. 94.5%, P < 0.05). Similarly, in the Non-anatomical group, the 5-year RFS of patients with negative MVI was also superior to that of patients with positive MVI (99% vs. 75.8%, P < 0.05). In addition to surgical methods, MVI may be another important factor affecting the 5-year RFS of patients with HAE.

ObjectiveTo study the application of thrombolysis diagram (TEG) and routine coagulation test in the evaluation of coagulation function in patients with hepatic hydatid.MethodsThe observation group consisted of 69 cases of hydatid liver patients undergoing elective combined segmenectomy, and the control group consisted of 69 healthy subjects. The correlation analysis of TEG, six coagulation items and PLT in the preoperative observation group and control group was conducted. The differences of TEG, hemagglutination six and PLT between the two groups were compared. TEG and coagulation function indexes of observation group were compared at different time during perioperative period.ResultsIn the control group, The time of blood cell aggregation (K) was negatively correlated with prothrombin time (PT), fibrinogen (FIB) and platelet count(PLT); The maximum strength of blood clot (MA) was positively correlated with PT, FIB and PLT; The rate of blood cell aggregation (Angle) is positively correlated with PT, FIB and PLT; the comprehensive index of blood coagulation (CI) was positively correlated with FIB and PLT. The reaction time of blood coagulation (R) of observation group was positively correlated with PT; MA was positively correlated with PT, FIB and PLT; MA was negatively correlated with thrombin time (TT). activated partial thromboplastin time (APTT), D-dimer (DD), PLT, R value, K value, Angle, MA and CI were compared between the two groups, and the differences were statistically significant (P<0.05). Compared with T1, APTT, R value, Angle and MA in observation group were significantly decreased at T2 and T3 (P<0.05); Compared with T1, PT, TT, FIB and K values had no significant changes (P>0.05).ConclusionThe coagulation function of liver hydatid patients was relatively low during the perioperative period, TEG is more sensitive to changes in perioperative coagulation function and can comprehensively understand the patient’s coagulation state.

Alveolar echinococcosis (AE), a lethal parasitic zoonosis mimicking malignant tumors, progresses via hepatic infiltration and metastatic spread, causing multiorgan failure. Despite its clinical resemblance to cancer, molecular drivers of its aggressiveness remain poorly defined. Recent studies highlight perilesional angiogenesis as pivotal for lesion invasiveness, mediated by VEGF-driven pathological vascularization. VEGF not only fuels parasitic proliferation by creating nutrient-rich microenvironments but also engages crosstalk with host-parasite interactions, including immune evasion by Echinococcus multilocularis, germinal layer hyperplasia, and periparasitic inflammation.Targeting the HIF-1α/VEGF/VEGFR2 axis emerges as a promising therapeutic strategy. Mechanistically, VEGF/VEGFR2 blockade may simultaneously disrupt angiogenesis-dependent parasitic expansion and survival pathways. Preclinical evidence shows that inhibiting HIF-1α (VEGF’s upstream regulator) suppresses metacestode proliferation and tissue invasion by starving lesions of vascular support while modulating immune-inflammatory responses. This dual action addresses both parasitic resource acquisition and host defence subversion.This review synthesizes molecular insights into HIF-1α/VEGF-mediated pathogenesis with clinical observations, proposing anti-angiogenic therapy as a rational adjunct to current treatments. By delineating VEGF’s role in sustaining parasitic metabolic demands and immune regulation, we underscore the translational potential of pathway-specific inhibitors. Such approaches could mitigate limitations of conventional therapies (e.g., benzimidazoles), particularly for advanced-stage AE with microvascular proliferation. Systematic analysis of angiogenesis signalling networks advances our understanding of AE’s “parasitic cancer” paradigm while guiding development of targeted interventions to improve patient outcomes.

Alveolar echinococcosis (AE), a zoonotic parasitic disease caused by Echinococcus multilocularis infection, predominantly colonizes the liver and may metastasize to the lungs or brain in advanced stages. Involvement of extrapulmonary sites such as the chest wall or subcutaneous tissues is exceedingly rare, even in endemic regions. The nonspecific clinical manifestations and imaging features of chest wall AE pose diagnostic challenges, necessitating histopathological confirmation. We present a case of a 48-year-old female admitted with a chief complaint of a right supra-mammary mass persisting for over 1 year. Imaging studies revealed a cystic lesion in the right chest wall and a hypodense hepatic lesion in the right lobe, suggestive of hydatid disease. The patient underwent combined hepatic segmentectomy and chest wall mass resection under general anesthesia. Histopathological examination confirmed AE infection in both hepatic and anterior chest wall specimens. The patient achieved complete recovery with no postoperative complications and was discharged uneventfully. Regular oral albendazole therapy has been maintained for 6 months postoperatively, with no recurrence to date.

BACKGROUND:Hepatic cystic and alveolar echinococcosis coinfections, particularly with concurrent abscesses and sinus tract formation, are extremely rare. This article presents a case of a patient diagnosed with this unique presentation, discussing the typical imaging manifestations of both echinococcosis types and detailing the diagnosis and surgical treatment experience thereof.CASE SUMMARY:A 39-year-old Tibetan woman presented with concurrent hepatic cystic and alveolar echinococcosis, accompanied by abdominal wall abscesses and sinus tract formation. Initial conventional imaging examinations suggested only hepatic cystic echinococcosis, but intraoperative and postoperative pathological examination revealed the coinfection. Following radical resection of the lesions, the patient's condition improved, and she was discharged soon thereafter. Subsequent outpatient follow-ups confirmed no recurrence of the hydatid lesion and normal surgical wound healing. Though mixed hepatic cystic and alveolar echinococcosis with abdominal wall abscesses and sinus tract formations are rare, the general treatment approach remains consistent with that of simpler infections of alveolar echinococcosis.CONCLUSION:Lesions involving the abdominal wall and sinus tract formation, may require radical resection. Long-term prognosis includes albendazole and follow-up examinations.

Alveolar echinococcosis (AE) is a chronic zoonotic parasitic disease caused by infection with Echinococcus multilocularis . AE is associated with a high mortality rate and poses a significant threat to human health. The primary treatment for AE is surgical resection of the lesions; however, owing to its long incubation period and insidious disease progression, many patients are diagnosed only after the onset of complications such as liver cirrhosis, jaundice, and portal hypertension, which preclude curative surgical intervention. For patients who are unwilling or unable to undergo surgery, lifelong administration of anti-AE medications is necessary. Benzimidazole compounds, such as albendazole and mebendazole, are the current mainstays of treatment, offering good efficacy. Nevertheless, these medications primarily inhibit parasite proliferation rather than eradicate the infection, and their long-term use can lead to significant drug-related toxic effects. Consequently, there is an urgent need to develop new therapeutic strategies that convey better efficacy and reduce the adverse effects associated with current treatments. Recent advancements in AE therapy include novel synthetic compounds such as antiviral agents, antibiotics, antineoplastic agents, immunosuppressants, and antiangiogenic agents, as well as natural compounds derived from traditional Chinese and Tibetan medicine. These new drugs show promising clinical potential because they interfere with parasitic metabolic pathways and cellular structures. This review aims to discuss recent research on AE drug therapy, including mechanisms of action, dosing regimens, signalling pathways, and therapeutic outcomes, with a goal of providing new insights and directions for the development of anti-AE drugs and summarizing current advancements in AE pharmacotherapy.

Introduction: Echinococcosis is a chronic zoonotic disease caused by tapeworms of the genus Echinococcus. The World Health Organization (WHO) has identified encapsulated disease as one of 17 neglected diseases to be controlled or eliminated by 2050. There is no accurate, early, non-invasive molecular diagnostic method to detect echinococcosis. The feasibility of circulating free DNA as a diagnostic method for echinococcosis has yielded inconclusive results in a number of published studies. However, there has been no systematic evaluation to date assessing the overall performance of these assays. We report here the first meta-analysis assessing the diagnostic accuracy of cfDNA in plasma, serum, and urine for echinococcosis. Methods: We systematically searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and WeiPu databases up to 17 January 2024, for relevant studies. All analyses were performed using RevMan 5.3, Meta-DiSc 1.4, Stata 17.0, and R 4.3.1 software. The sensitivity, specificity, and other accuracy indicators of circulating free DNA for the diagnosis of echinococcosis were summarized. Subgroup analyses and meta-regression were performed to identify sources of heterogeneity. Results: A total of 7 studies included 218 patients with echinococcosis and 214 controls (156 healthy controls, 32 other disease controls (non-hydatid patients), and 26 non-study-targeted echinococcosis controls were included). Summary estimates of the diagnostic accuracy of cfDNA in the diagnosis of echinococcosis were as follows: sensitivity (SEN) of 0.51 (95% CI: 0.45-0.56); specificity (SPE) of 0.99 (95% CI: 0.97-0.99); positive likelihood ratio (PLR) of 11.82 (95% CI: 6.74-20.74); negative likelihood ratio (NLR) of 0.57 (95% CI: 0.41-0.80); diagnostic ratio (DOR) of 36.63 (95% CI: 13.75-97.59); and area under the curve (AUC) value of 0.98 (95% CI: 0.96-1.00). Conclusion: Existing evidence indicates that the combined specificity of circulating cfDNA for echinococcosis is high. However, the combined sensitivity performance is unsatisfactory due to significant inter-study heterogeneity. To strengthen the validity and accuracy of our findings, further large-scale prospective studies are required.

Echinococcosis is a zoonotic parasitic disease caused by Escherichia larvae. It frequently involves the liver (70%-75%), followed by the lungs (15%-20%), and occasionally the brain, heart, spleen, bone, and other organs. The main pathogenic forms of human echinococcosis currently include cystic echinococcosis (CE) and alveolar echinococcosis (AE). CE is globally distributed, while the distribution of AE is generally restricted to the northern hemisphere. In China, CE accounts for 75% of all echinococcosis cases. With rapid advances in surgical techniques in recent decades, the surgical strategy for CE has changed, especially with the continuous improvement of surgical methods and the expansion of surgical contraindications. To further understand the changes in surgical treatment strategies for hepatic CE, we interpreted and analyzed the existing literature addressing the surgical treatment of hepatic CE both domestically and abroad and briefly summarized them in chronological order. This review aims to provide a deeper understanding of the progress in the surgical treatment of hepatic CE to provide clearer avenues for its clinical diagnosis and treatment.

Objective:To investigate the clinical effect of improved right hemihepatectomy（MRH）in the treatment of hepatocellular carcinoma（HCC）under the guidance of indocyanine green（ICG）tracer and 3D visualization technology.Methods:Clinical data of 92 patients with HCC who received MRH from January 2018 to December 2020 were retrospectively analyzed，and the patients were divided into traditional group（n=50）and combined group（n=42）according to whether they were guided by ICG tracer combined with 3D visualization technology. Conventional imaging was used to evaluate MRH in the traditional group，and ICG tracer combined with 3D visualization was used to guide MRH in the combined group. The data were processed by SPSS 22.0 software，and measurement data such as perioperative indicators and liver function indicators were represented by（xˉ±s）. Repeated measurement analysis of variance was performed for liver function indicators，and independent sample t test was performed for other indicators. The statistical data of postoperative complications were chi-square test. Survival analysis was performed by Kaplan-Meier method and Log-Rank test. P<0.05 was considered statistically significant.Results:Operation time，hilar occlusion time and intraoperative blood loss in combination group were significantly lower than those in traditional group（P<0.05）. There was no interaction between time and method at albumin（ALB），total bilirubin（TBil）and alanine aminotransferase（ALT）levels（P>0.05），but the main effect of time and method was significant at ALB，TBil and ALT levels（P<0.05）. The total incidence of postoperative complications in the combination group was significantly lower than that in the traditional group（11.9% vs. 30.0%，P<0.05）. During the follow-up period，the cumulative overall survival rate and disease-free survival rate of the combination group were significantly higher than those of the traditional group（P<0.05）.Conclusion:The treatment of HCC with MRH under the guidance of ICG tracer and 3D visualization technology can not only effectively shorten the operation time and reduce intraoperative injury，but also benefit the postoperative liver function recovery of patients，reduce the occurrence of postoperative complications and improve the prognosis of patients.

OBJECTIVE:To retrospectively analyze the effects of radical lesion resection and quasi radical lesion resection on the quality of life of patients with advanced hepatic alveolar echinococcosis. METHODS:Through the existing HIS system of Qinghai Provincial People's Hospital, 104 patients with hepatic alveolar echinococcosis who underwent surgical treatment in our hospital from January 2012 to December 2017 and completed the quality of life questionnaire were selected as the research objects. The above cases were divided into radical group (n = 51) and quasi-radical group (n = 53) according to different surgical methods (degree of radical cure). The quality of life of patients with hydatidosis was measured by interview or telephone follow-up. The preoperative indexes, intraoperative conditions and postoperative recovery indicators of the two groups were observed, such as Child-Puhg grade, PNM classification, scope of hepatectomy, intraoperative bleeding, Clavien grade, incidence of complications, 5-year recurrence rate and total score of quality of life and so on. RESULTS:There was no significant difference between the two groups in general data such as age, gender, hydatid size, Child-Puhg grade and preoperative liver function (P > 0.05). However, there was a statistically significant difference in PNM classification between the two groups (P < 0.05). There were significant differences in intraoperative bleeding, postoperative liver function recovery, Clavien grade of complication severity and 5-year recurrence rate between the two groups (P < 0.05). There was no significant difference in postoperative quality of life between the two groups (P > 0.05). CONCLUSION:For patients with advanced hepatic alveolar echinococcosis whose objective cannot be achieved by conventional hepatectomy, quasi-radical resection of the lesion can not only reduce the risk and difficulty of surgery, but also the quality of life of the patients may be as good as that of radical resection.

Pathogenesis of hepatic Echinococcosis is induced by parasitism of Echinococcus species.Generally speaking, there are two types of the disease--hepatic cystic echinococcosis which is caused by E. granulosus and hepatic alveolar echinococcosis which is caused by E. multilocularis.Either of the two types is much clinically popular.However, simultaneous appearance of both the two types can be rarely seen.In this study, we reported a case of co-infection of both hepatic cystic and alveolar echinococcosis, aiming to offer experience in diagnosing and treating the co-infection by depicting the clinical characteristics, imaging manifestations and therapies.

Background:Echinococcosis (E) is a zoonotic parasitic disease caused by the larval morphology of echinococcosis tapeworms. Among the recognized species, two are of medical importance-E. granulosus and E. multilocularis-causing cystic echinococcosis (CE) and alveolar echinococcosis (AE) in humans, respectively. Diagnosis of AE is based on clinical manifestation and epidemiological data, imaging techniques, histopathology and/or nucleic acid detection, and serology. At present, WHO guidelines suggest that benzimidazoles (BMZ) are mandatory in all AE patients, temporarily after complete resection of the lesions and for life in all other AE cases. Interventional procedures should be preferred to palliative surgery whenever possible, and radical surgery is the first choice in all cases suitable for total resection of the lesion. However, some research centers have proposed that local ablation (LA) including radiofrequency ablation (RFA) and microwave ablation (MWA) is no less effective than radical surgery or better than simple medication in the early stage hepatic AE (WHO-IWGE PNM classification of AE: P1N0M0). This study attempted to compare the real efficacy of the above treatment methods, so as to find the best treatment for this kind of patient. Methods:The data of patients with hepatic AE who underwent laparoscopic hepatectomy (LH), RFA, and MWA in Qinghai Provincial People's Hospital from January 2015 to January 2021 were collected. At the same time, the cases treated with Albendazole (ABZ) were collected together with the institution for disease control and prevention. According to the treatment methods, the above cases were divided into LH group, RFA group, MWA group, and medication group. The basic data and postoperative recovery indices of the four groups were compared, respectively. Results:A total of 199 patients with hepatic AE were enrolled in this study, including 90 males and 109 females. The youngest was 5 years old and the oldest was 66 years old, with an average of 33.41±14.64 years old. 20.6% of the patients had hepatitis B (41/ 199). A total of 45 patients underwent ultrasound-guided RFA, 47 patients underwent ultrasound-guided MWA, 51 patients were treated with ABZ, and 56 patients underwent LH. There were no significant differences in baseline characteristics among the four groups (p > 0.05). The RFA group and MWA group were more advantageous than the LH group regarding operation time and incidence of postoperative complications (p < 0.05). But recurrence rate of the lesion in the LH group was significantly lower than the RFA group, MWA group, and medication group. However, there was no significant difference in recurrence-free survival time among the four groups (p >0.05). Conclusion:LH has a significant effect in the treatment of early-stage hepatic AE, especially in terms of recurrence which is significantly better than LA and medication alone. Follow-up and adherence to ABZ therapy are essential if conservative treatment is to achieve better outcomes.

[This corrects the article DOI: 10.3389/fsurg.2021.821373.].

目的 检测环状核糖核酸(circular RNA,cicrRNA)hsa_circ_0006950在胰腺癌(pancreatic cancer,PC)中的表达,探讨其对胰腺癌细胞增殖、迁移的影响及其潜在分子作用机制.方法 利用实时荧光定量PCR(qRT-PCR)检测hsa_circ_0006950在胰腺癌组织及细胞中的相对表达水平;转染hsa_circ_0006950干扰载体构建低表达细胞系,通过CCK-8实验、克隆斑点形成实验和Transwell实验检测hsa_circ_0006950对胰腺癌细胞增殖、克隆形成及迁移的影响;利用生物信息学网站预测hsa_circ_0006950的miRNA分子靶标及其调控网络(hsa_circ_0006950-miR-124-3p-EZH2),双荧光素酶基因报告实验验证hsa_circ_0006950和miR-124-3p,miR-124-3p和EZH2的靶向结合关系;转染过表达/干扰miR-124-3p和过表达EZH2细胞系,探究miR-124-3p和EZH2及hsa_circ_0006950调控miR-124-3p/EZH2轴对胰腺癌细胞克隆形成及迁移的影响.结果 胰腺癌组织中hsa_circ_0006950表达明显高于癌旁正常组织(3.57±0.52 vs 1.01±0.03),差异有统计学意义(t=21.980,P<0.001).胰腺癌细胞PANC-1(7.51±0.62),AsPC-1(5.26±0.45),Capan-2(3.69±0.38),SW1990(3.25±0.32)and BXPC-3(3.86±0.35)中hsa_circ_0006950相对表达明显高于正常胰腺导管上皮细胞HPDE6-C7(1.00±0.01)中的表达,差异有统计学意义(F=88.585,P<0.001).与对照组相比,干扰hsa_circ_0006950表达组细胞增殖能力(0.79±0.17 vs 1.83±0.42),克隆形成率(51.42％±5.84％vs 78.76％±13.65％)和迁移数目(104.64±24.73 vs 218.21±31.57)明显降低,差异均有统计学意义(t=3.976,3.190,4.905,P=0.016,0.033,0.008).miR-124-3p是hsa_circ_0006950的下游靶基因,EZH2是miR-124-3p的直接靶标.hsa_circ_0006950靶向负调控miR-124-3p,miR-124-3p靶向负调控EZH2.与对照组相比,过表达miR-124-3p组PC细胞增殖(0.21±0.16 vs 1.75±0.47),克隆形成率(47.85％±4.13％vs 81.54％±2.33％)和细胞迁移数目(118.74±24.65 vs 202.36±31.45)明显降低,差异均有统计学意义(t=5.378,14.317,3.390,均P<0.001);共转染过表达EZH2后,miR-124-3p对细胞增殖、克隆形成率及迁移能力的抑制作用被逆转.在干扰hsa_circ_0006950组细胞中同时下调miR-124-3p或过表达EZH2后,hsa_circ_0006950对细胞克隆形成及迁移的抑制作用被逆转恢复.结论 胰腺癌中hsa_circ_0006950显著高表达,抑制其表达可以抑制胰腺癌细胞的增殖及迁移;hsa_circ_0006950可能通过靶向下调miR-124-3p表达,进而上调EZH2表达来发挥作用,参与胰腺癌的发生发展.

[This corrects the article DOI: 10.3389/fpubh.2021.816704.].